XTL Biopharmaceuticals (NASDAQ:XTLB) Stock Passes Above 50-Day Moving Average – What’s Next?

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)’s stock price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $2.68 and traded as high as $2.87. XTL Biopharmaceuticals shares last traded at $2.7120, with a volume of 2,450 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, XTL Biopharmaceuticals currently has an average rating of “Sell”.

XTL Biopharmaceuticals Stock Performance

The business has a 50-day simple moving average of $2.69 and a 200 day simple moving average of $2.81. The firm has a market cap of $6.16 million, a P/E ratio of -4.38 and a beta of 1.46.

XTL Biopharmaceuticals (NASDAQ:XTLB) last released its quarterly earnings data on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. The business had revenue of ($0.26) million during the quarter.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.